COVID SCIENCE: One vaccine dose might be enough for COVID-19 survivors

07/02/2021 8:00:00 PM

Covıd 19, Covıd-19

COVID SCIENCE: One vaccine dose might be enough for COVID19 survivors

Watch more in iWantTFC In one study of 59 healthcare workers who recovered from COVID-19 and received one of the vaccines, antibody levels after the first shot were higher than levels usually seen after two doses in people without a history of COVID-19. 

In a separate study, researchers found that 41 COVID-19 survivors developed "high antibody titers within days of vaccination," and those levels were 10 to 20 times higher than in uninfected, unvaccinated volunteers after just one vaccine dose. 

Read more:
ABS-CBN News Channel »

Regeneron says its COVID-19 antibody cocktail helps prevent symptomatic COVID-19New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said. investing with maria D bate was the best thing that have ever happened to me cause I ear u p to $5000 with $400 through forex trading she's the best I know of , after I was scammed , thanks very much mam . well if you are interested click and message her 👇👇👇 mariadbates2

COVID SCIENCE: Pollen level in air linked to COVID-19 rates

PH confirms 19 more cases of UK Covid-19 variant; total now 44The DOH confirmed an additional 19 cases of the more transmissible UK variant of the new coronavirus, which brings the total number of confirmed cases of the variant in the country to 44. | cgonzalesINQ cgonzalesINQ And we’re opening cinemas and arcades. Yey! cgonzalesINQ Ugh and still no supply contracts for the vaccines

DOH reports 19 new cases of UK COVID-19 variant in the PH

COVID-19 UK variant infects 19 more in PHMANILA, Philippines — The Department of Health (DOH) said it had recorded 19 new infections of the B.1.1.7 variant of the coronavirus first detected in the United Kingdom, which brought the total Once again ,be cause of govt. negligence.

COVID-19 survivors might only need one shot of the new vaccines from Moderna Inc and Pfizer/BioNTech , instead of the usual two doses, because their immune systems have gotten a head start on learning to recognize the virus, according to two separate reports posted this week on medRxiv ahead of peer review.endIndex: (CNN) -- New Phase 3 trial data finds a single shot of Regeneron's COVID-19 antibody cocktail was able to prevent symptomatic COVID-19 among people exposed to the virus, the company said Monday.The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Palace: MVIS no longer mandatory Breakdown of new cases According to DOH, the indicated addresses of three of the 19 cases—a 10-year-old boy, a 54-year-old woman, and a 33 year-old man—is in Davao Region.

Watch more in iWantTFC In one study of 59 healthcare workers who recovered from COVID-19 and received one of the vaccines, antibody levels after the first shot were higher than levels usually seen after two doses in people without a history of COVID-19.  In a separate study, researchers found that 41 COVID-19 survivors developed "high antibody titers within days of vaccination," and those levels were 10 to 20 times higher than in uninfected, unvaccinated volunteers after just one vaccine dose. In the new trial, the drug, named REGEN-COV, reduced risk of symptomatic infections by 81%, the company said Monday in a news release.  "The antibody response to the first vaccine dose in individuals with pre-existing immunity is equal to or even exceeds" levels found in uninfected individuals after the second vaccine dose, the authors of that paper said. The effect was not connected with pollen allergies, the researchers said.  "Changing the policy to give these individuals only one dose of vaccine would not negatively impact on their antibody titers, spare them from unnecessary pain and free up many urgently needed vaccine doses," they said. Each participant received one dose of the drug or a placebo, which does nothing, administered as an injection through the skin.  Gout drug shows promise for mildly ill COVID-19 patients Colchicine, an anti-inflammatory drug used to treat gout and other rheumatic diseases, reduced hospitalizations and deaths by more than 20% in COVID-19 patients in a large international trial. The other case is a 76-year-old woman with exposure to a positive case last January 21 and is currently experiencing mild symptoms.

  COVID-19 patients with mild illness and at least one condition that put them at high risk for complications, such as diabetes or heart disease, received either colchicine or a placebo for 30 days. The drug provided 72% protection against symptomatic infections in the first week and 93% protection in subsequent weeks, Regeneron said.  "As we cannot completely avoid pollen exposure, we .  Overall, the risk of hospitalization or death was statistically similar in the two groups.  But among the 4,159 patients whose coronavirus infections had been diagnosed with a gold-standard PCR test, death or hospital admission occurred in 4. Those who received the antibody cocktail and experienced a symptomatic infection resolved their symptoms in one week, the company said, compared to three weeks among those who received a placebo.6% of those on colchicine versus 60% of those who got a placebo. encourage high-risk individuals to wear particle filter masks during high pollen concentrations," said coauthor Athanasios Damialis of Technical University of Munich, in Augsburg, Germany.  After taking patients' other risk factors into account, colchicine was associated with a statistically significant 25% risk reduction, the researchers reported on medRxiv ahead of peer review. Myron Cohen, who leads the monoclonal antibody efforts for the COVID Prevention Network and is the director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, said in a statement. “Case investigation and contact tracing have been initiated to verify reported information and trace possible sources of infection.

Patients taking colchicine also had fewer cases of pneumonia.  "Given that colchicine is inexpensive, taken by mouth, was generally safe in this study, and does not generally need lab monitoring during use, it shows potential as the first oral drug to treat COVID-19 in the outpatient setting," the researchers said." Adverse events occurred in 20% of patients who received the antibody drug and 29% of those who received a placebo, Regeneron said. The researchers studied 84 pregnant women, 31 breastfeeding women, and 16 non-pregnant women who received the vaccines.  Oxford/AstraZeneca vaccine might work better with doses months apart Among recipients of the COVID-19 vaccine from Oxford University and AstraZeneca, prolonging the interval between the first and second doses led to better results, researchers said in a paper posted on Monday ahead of peer-review by The Lancet on its preprint site.  Watch more in iWantTFC For volunteers aged 18 to 55, vaccine efficacy was 82. None of the four deaths in the trial -- two among those who received the drug and two who received a placebo -- were due to COVID-19 or the drug.4% with 12 or more weeks between doses, compared to 54.  She added that the study addressed an important question as COVID-19 vaccines are rolled out, given that there is currently "limited to no data on how they work in this population.

9% when the booster was given within 6 weeks after the first dose. The drug is currently authorized to be administered as an IV, which takes longer and may be part of the reason why uptake of the treatment has been limited.  The longest interval between doses given to older volunteers was 8 weeks, so there were no data for the efficacy of a 12-week dosing gap in that group.  Europe's medicine regulator has said there is not enough data to determine how well the vaccine will work in people over 55. A single shot reduced the risk of progressing to symptomatic COVID-19 by 31% overall.  Rapid test can screen for variants of concern A new test can rapidly screen thousands of nasopharyngeal swab samples for the concerning, more contagious new virus variants first identified in the UK, South Africa and Brazil, researchers said. Given their findings, the authors say "a second dose given after a three-month period is an effective strategy .. Participants received the treatment or a placebo, and the trial showed that the duration of symptoms was shortened and viral levels were reduced in those who received the antibody cocktail.

.  "Our next job, already mostly completed, will be to add to the test so that a second mutation . and may be the optimal for rollout of a pandemic vaccine when supplies are limited in the short term. However, the US government said last month it will no longer distribute bamlanivimab for use on its own because of a sustained increase in coronavirus variants in the United States."  (Reporting by Nancy Lapid and Alistair Smout; Editing by Bill Berkrot) .